Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)
Keros Therapeutics' (KROS) quarterly Tax Provisions came in at -$1.5 million in Q4 2025, down 604.67% YoY from $300000.0 in Q4 2024, and down 6.32% on a QoQ basis from -$1.4 million in Q3 2025.
Keros Therapeutics (KROS) Tax Provisions (2020 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 4 years of Tax Provisions data on file, last reported at -$1.5 million in Q4 2025.
- Quarterly Tax Provisions fell 604.67% year-over-year to -$1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (up 1527.67% YoY) and the FY2025 annual result came in at $4.9 million, up 1527.67% from the prior year.
- Tax Provisions eased to -$1.5 million in Q4 2025, from -$1.4 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $10.0 million in Q1 2025 to a low of -$2.2 million in Q2 2025.
- A 3-year average of $899250.0 and a median of $6000.0 in 2021 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2021 — Tax Provisions surged 129.07% — and 2025, when it tumbled 604.67%.
- Tracing KROS's Tax Provisions over 3 years: stood at $2.0 million in 2021, then slumped by 84.99% to $300000.0 in 2024, then plunged by 604.67% to -$1.5 million in 2025.
- The last three Tax Provisions figures came in at -$1.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.42 Mn |
| Jun 30, 2025 | -2.22 Mn |
| Mar 31, 2025 | 10.04 Mn |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | -38,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Mar 31, 2020 | -172,000.00 |